Trump lashes out at scientists whose findings contradict him

Image
AP Washington
Last Updated : May 22 2020 | 11:01 AM IST

"A Trump enemy statement, he said of one study.

A political hit job, he said of another.

As President Donald Trump pushes to reopen the country despite warnings from doctors about the consequences of moving too quickly during the coronavirus crisis, he has been lashing out at scientists whose conclusions he doesn't like.

Twice this week, Trump has not only dismissed the findings of studies, but suggested without evidence that their authors were motivated by politics and out to undermine his efforts to roll back coronavirus restrictions.

First it was a study funded in part by his own government's National Institutes of Health that raised alarms about the use of hydroxychloroquine, finding higher overall mortality in coronavirus patients who took the drug while in Veterans Administration hospitals.

Trump and many of his allies had been trumpeting the drug as a miracle cure and Trump this week revealed that he has been taking it to try to ward off the virus despite an FDA warning last month that it should only be used in hospital settings or clinical trials because of the risk of serious side effects, including life-threatening heart problems.

If you look at the one survey, the only bad survey, they were giving it to people that were in very bad shape. They were very old, almost dead," Trump told reporters Tuesday.

It was a Trump enemy statement." He offered similar pushback Thursday to a new study from Columbia University's Mailman School of Public Health.

It found that more than 61 per cent of COVID-19 infections and 55 per cent of reported deaths nearly 36,000 people could have been been prevented had social distancing measures been put in place one week sooner. Trump has repeatedly defended his administration's handling of the virus in the face of persistent criticism that he acted too slowly.

Columbia's an institution that's very liberal," Trump told reporters Thursday. "I think it's just a political hit job, you want to know the truth.

Trump has long been skeptical of mainstream science dismissing man-made climate change as a hoax, suggesting that noise from wind turbines causes cancer, and claiming that exercise can deplete a body's finite amount of energy. It's part of a larger skepticism of expertise and backlash against elites that has become increasingly popular among Trump's conservative base.

But undermining Americans' trust in the integrity and objectivity of scientists is especially dangerous during a pandemic when the public is relying on its leaders to develop policies based on the best available information, said Larry Gostin, a Georgetown University law professor who is an expert in public health.

If the president is politicizing science, if he's discounting health experts, then the public is going to be fearful and confused," Gostin said, calling it dismaying." The White House rejected that thinking, noting that Trump has followed his administration's public health officials' recommendations through much of the crisis.

Any suggestion that the president does not value scientific data or the important work of scientists is patently false as evidenced by the many data-driven decision he has made to address the COVID-19 pandemic, including cutting off travel early from highly-infected populations, expediting vaccine development, issuing the 15-day and later 30-day guidance to 'slow the spread,' and providing governors with a clear, safe road map to opening up America again," said White House spokesman Judd Deere.

Yet Trump has made clear that, at least when it comes to hydroxychloroquine, he has prioritized anecdotal evidence, including a letter he told reporters he'd received from a doctor in Westchester, New York, claiming success with the drug.

Asked this week what evidence he had that the drug was effective in preventing COVID-19, Trump responded: "Are you ready? Here's my evidence: I get a lot of positive calls about it."

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 22 2020 | 11:00 AM IST

Next Story